Literature DB >> 33246326

Monocytic MDSCs skew Th17 cells toward a pro-osteoclastogenic phenotype and potentiate bone erosion in rheumatoid arthritis.

Shixian Chen1,2, Chunqing Guo3,4, Ran Wang1,2, Zhitao Feng1, Zheng Liu3,4, Lisheng Wu1, Di Zhao1, Songyuan Zheng1, Feilong Chen1, Dingding Zhang1, Juan Xu1, Junqing Zhu2, Xiaoguang Chen5, Zhanguo Li6, Christopher M Wise7, Juan Li1,2, Xiang-Yang Wang3,4,8.   

Abstract

OBJECTIVES: While myeloid-derived suppressor cells (MDSCs) were previously shown to promote a proinflammatory T helper (Th) 17 response in autoimmune conditions, a potential impact of the MDSC-Th17 immune axis on abnormal bone destruction in RA remains largely unknown.
METHODS: We investigated the correlation between the frequency of MDSCs or its subsets and joint destruction in RA patients. The reciprocal actions of patient-derived MDSCs and Th17 cells were studied using osteoclast (OC) differentiation and bone resorption assays in vitro, which were further validated using mouse models of RA. Contribution of MDSCs to osteoclastogenesis and bone erosion in vivo was determined by depletion or transfer of MDSCs.
RESULTS: Human MDSCs, particularly monocytic MDSCs (M-MDSCs), exhibit inherent OC-differentiating capacity and positively correlate with clinical bone erosion in RA patients. Strikingly, patient-derived M-MDSCs can program Th17 cells towards a pro-osteoclastogenic phenotype, which in return potentiates OC differentiation via the receptor activator of nuclear factor κΒ ligand (RANK-L)-RANK signalling. This enhanced osteolysis driven by the reciprocal actions of M-MDSCs and Th17 cells is further confirmed using mouse models of RA. Selective depletion of M-MDSCs significantly ameliorates osteoclastogenesis and disease severity in arthritic mice, whereas transfer of M-MDSCs aggravates bone erosion associated with increased OCs in recipient mice.
CONCLUSION: Our findings highlight the functional plasticity of MDSCs and identify a novel pro-osteoclastogenic pathway governed by interplay between myeloid cells and T lymphocytes in autoimmune RA.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Th17; bone erosion; myeloid-derived suppressor cell; osteoclast; rheumatoid arthritis

Year:  2021        PMID: 33246326      PMCID: PMC8121448          DOI: 10.1093/rheumatology/keaa625

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  35 in total

1.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis.

Authors:  Wataru Fujii; Eishi Ashihara; Hideyo Hirai; Hidetake Nagahara; Naoko Kajitani; Kazuki Fujioka; Ken Murakami; Takahiro Seno; Aihiro Yamamoto; Hidetaka Ishino; Masataka Kohno; Taira Maekawa; Yutaka Kawahito
Journal:  J Immunol       Date:  2013-06-26       Impact factor: 5.422

3.  Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation.

Authors:  Hui Zhang; Shuang Wang; Yuefang Huang; Hongyue Wang; Jijun Zhao; Felicia Gaskin; Niansheng Yang; Shu Man Fu
Journal:  Clin Immunol       Date:  2015-02-11       Impact factor: 3.969

4.  Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis.

Authors:  Chunqing Guo; Fanlei Hu; Huanfa Yi; Zhitao Feng; Changzheng Li; Lianjie Shi; Yingni Li; Hongjiang Liu; Xiaofei Yu; Hongxia Wang; Juan Li; Zhanguo Li; Xiang-Yang Wang
Journal:  Ann Rheum Dis       Date:  2014-11-04       Impact factor: 19.103

Review 5.  Targeting Interleukin-6 Signaling in Clinic.

Authors:  Sujin Kang; Toshio Tanaka; Masashi Narazaki; Tadamitsu Kishimoto
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

6.  Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.

Authors:  Anandi Sawant; Jessy Deshane; Joel Jules; Carnella M Lee; Brittney A Harris; Xu Feng; Selvarangan Ponnazhagan
Journal:  Cancer Res       Date:  2012-12-14       Impact factor: 12.701

7.  Significance of serum TRACP in rheumatoid arthritis.

Authors:  Anthony J Janckila; David H Neustadt; Lung T Yam
Journal:  J Bone Miner Res       Date:  2008-08       Impact factor: 6.741

8.  Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus.

Authors:  Hao Wu; Yu Zhen; Zhanchuan Ma; Huimin Li; Jinyu Yu; Zhong-Gao Xu; Xiang-Yang Wang; Huanfa Yi; Yong-Guang Yang
Journal:  Sci Transl Med       Date:  2016-03-23       Impact factor: 17.956

9.  Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling.

Authors:  Nataša Obermajer; Jeffrey L Wong; Robert P Edwards; Kong Chen; Melanie Scott; Shabaana Khader; Jay K Kolls; Kunle Odunsi; Timothy R Billiar; Pawel Kalinski
Journal:  J Exp Med       Date:  2013-07-01       Impact factor: 14.307

10.  Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction.

Authors:  Kojiro Sato; Ayako Suematsu; Kazuo Okamoto; Akira Yamaguchi; Yasuyuki Morishita; Yuho Kadono; Sakae Tanaka; Tatsuhiko Kodama; Shizuo Akira; Yoichiro Iwakura; Daniel J Cua; Hiroshi Takayanagi
Journal:  J Exp Med       Date:  2006-11-06       Impact factor: 14.307

View more
  1 in total

1.  Pseudolycorine chloride ameliorates Th17 cell-mediated central nervous system autoimmunity by restraining myeloid-derived suppressor cell expansion.

Authors:  Gan Zhang; Xinying Zhu; Fan Yang; Juan Li; Xiao Leng; Chunfen Mo; Limei Li; Yantang Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.